2/11
08:00 am
evgn
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
Low
Report
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
2/10
01:20 pm
evgn
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
Medium
Report
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
2/10
08:00 am
evgn
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
High
Report
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
2/9
08:00 am
evgn
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
Medium
Report
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
2/4
10:00 pm
evgn
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
High
Report
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
2/4
08:19 am
evgn
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer [Yahoo! Finance]
High
Report
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer [Yahoo! Finance]
2/4
08:00 am
evgn
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
Low
Report
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
1/7
07:13 am
evgn
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders [Yahoo! Finance]
Medium
Report
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders [Yahoo! Finance]
1/7
07:00 am
evgn
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
Medium
Report
Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders
12/30
08:23 am
evgn
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development [Yahoo! Finance]
Low
Report
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development [Yahoo! Finance]
12/30
07:00 am
evgn
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
Medium
Report
Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development
11/20
07:00 am
evgn
Evogene Reports Third Quarter 2025 Financial Results
Medium
Report
Evogene Reports Third Quarter 2025 Financial Results